EBR Systems Inc (ASX:EBR)

ALERT: Price-sensitive ASX Announcement for EBR

Current share price for EBR : $0.385 -0.785 (-67.09%)⁺

Announcement

First Two Patients Enrolled in WiSE-UP Post-Approval Study

Release

6 Nov 2025 9:06AM

Price at Release

$1.170

Full Release

Summary

EBR Systems Inc., the developer of the world’s only wireless cardiac pacing system for heart failure, announced the enrolment of the first two patients in the WiSE-UP post-approval study. This observational study aims to evaluate real-world outcomes for heart failure patients using the FDA-approved WiSE System that employs left ventricular endocardial pacing for cardiac resynchronization therapy. The study will track over 300 patients across 50 centers for five years, gathering both short- and long-term performance data. The initiation of this study marks a significant milestone in advancing cardiac resynchronization therapy, with key contributions from Dr. Devi Nair and Dr. Niraj Varma leading the efforts. The study is anticipated to provide crucial clinical insights and further establish the efficacy of the WiSE System in practical settings.

Key Points

EBR Systems Inc. announced the first two patients enrolled in WiSE-UP post-approval study.
The study evaluates real-world outcomes for heart failure patients using WiSE System.
WiSE technology eliminates the need for cardiac pacing leads.
The WiSE-UP study will involve over 300 patients across 50 centers over five years.
Dr. Devi Nair and Dr. Niraj Varma play significant roles in the study.
The study provides both short- and long-term performance metrics.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.